StockData
Amgen Inc logo

Amgen Inc (AMGN) operating KPIs

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)

Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%

Amgen bLINCYTO (blinatumomab — CD19 BiTE Immuno-Oncology, ALL) — Worldwide product sales ($M) ($M)

Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail

QuarterlyAnnual
Latest, Q2 2026
472
Period ended Jun 30, 2026
Change on a year earlier
+22.9%
384 in Q2 2025
History
36 quarters
Since Q3 2017
Sources
27
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedBLINCYTO (blinatumomab — CD19 BiTE Immuno-Oncology, ALL) — Worldwide product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026472+22.9%Form 10-Q (filed 2026-08-05) ↗
Q1 2026Mar 31, 2026415+12.2%Form 10-Q (filed 2026-05-01) ↗
Q4 2025Dec 31, 2025413+8.4%Form 10-K (filed 2026-02-13) ↗
Q3 2025Sep 30, 2025392+19.9%Form 10-Q (filed 2025-11-05) ↗
Q2 2025Jun 30, 2025384+45.5%Form 10-Q (filed 2026-08-05) ↗
Q1 2025Mar 31, 2025370+51.6%Form 10-Q (filed 2026-05-01) ↗
Q4 2024Dec 31, 2024381+58.1%Form 10-K (filed 2026-02-13) ↗
Q3 2024Sep 30, 2024327+48.6%Form 10-Q (filed 2025-11-05) ↗
Q2 2024Jun 30, 2024264+28.2%Form 10-Q (filed 2025-08-06) ↗
Q1 2024Mar 31, 2024244+25.8%Form 10-Q (filed 2025-05-02) ↗
Q4 2023Dec 31, 2023241+47.0%Form 10-K (filed 2026-02-13) ↗
Q3 2023Sep 30, 2023220+54.9%Form 10-Q (filed 2024-10-31) ↗
Q2 2023Jun 30, 2023206+48.2%Form 10-Q (filed 2024-08-07) ↗
Q1 2023Mar 31, 2023194+40.6%Form 10-Q (filed 2024-05-03) ↗
Q4 2022Dec 31, 2022164+24.2%Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗
Q3 2022Sep 30, 2022142+13.6%Form 8-K (amgn-2022930earningsrelease.htm, filed 2022-11-03) ↗

Breakdown

What makes up blincyto (blinatumomab — cd19 bite immuno-oncology, all) — worldwide product sales ($m)

Cite this data

StockData. (2026). Amgen BLINCYTO (blinatumomab — CD19 BiTE Immuno-Oncology, ALL) — Worldwide product sales ($M) ($M), quarterly Q3 2017–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod_blincyto_ww

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.